EUVIMEDScopri EUVIMED
ÜbersichtsarbeitOpen access · CC BY 4.0

Glial fibrillary acidic protein in Alzheimer’s disease: a narrative review

Florine Leipp iD, Jérôme Vialaret, Pablo Mohaupt, Salomé Coppens, Aurore Jaffuel, Ann-Christin Niehoff, Sylvain Lehmann iD, Christophe Hirtz

Brain Communications · 2024-10-30 · 6 (6)

DOI: 10.1093/braincomms/fcae396 ↗

At a glance

Übersichtsarbeit in Brain Communications, published online on 2024-11-07. Written by Florine Leipp and 7 co-authors. Institution: Shimadzu France SAS France, Noisiel, France. Cited 93 times so far (Crossref); 157 references. The full text is freely available (open access, CC BY 4.0). Funded by: Shimadzu Corporation.

AbstractSubjectsDati bibliograficiCiteRelated studies

Abstract (original language)

Astrocytes are fundamental in neural functioning and homeostasis in the central nervous system. These cells respond to injuries and pathological conditions through astrogliosis, a reactive process associated with neurodegenerative diseases such as Alzheimer’s disease. This process is thought to begin in the early stages of these conditions. Glial fibrillary acidic protein (GFAP), a type III intermediate filament protein predominantly expressed in astrocytes, has emerged as a key biomarker for monitoring this response. During astrogliosis, GFAP is released into biofluids, making it a candidate for non-invasive diagnosis and tracking of neurodegenerative diseases. Growing evidence positions GFAP as a biomarker for Alzheimer’s disease with specificity and disease-correlation characteristics comparable to established clinical markers, such as Aβ peptides and phosphorylated tau protein. To improve diagnostic accuracy, particularly in the presence of confounders and comorbidities, incorporating a panel of biomarkers may be advantageous. This review will explore the potential of GFAP within such a panel, examining its role in early diagnosis, disease progression monitoring and its integration into clinical practice for Alzheimer’s disease management.

Subjects

Author keywords

Alzheimer’s diseaseastrocytesbiomarkerglial fibrillary acidic proteinreactive astrogliosis

Authors and institutions

  • Shimadzu France SAS France, Noisiel, France.
  • IRMB-PPC, INM, Univ Montpellier, CHU Montpellier, INSERM CNRS, Montpellier, France.
  • Shimadzu Europa GmbH, Duisburg, Germany.

ORCID profiles: Florine Leipp, Sylvain Lehmann

Funding

  • Shimadzu Corporation

Cite

APA

Leipp, F., Vialaret, J., Mohaupt, P., Coppens, S., Jaffuel, A., Niehoff, A. C., Lehmann, S., & Hirtz, C. (2024). Glial fibrillary acidic protein in Alzheimer’s disease: a narrative review. Brain Communications, 6(6). https://doi.org/10.1093/braincomms/fcae396

Vancouver

Leipp F, Vialaret J, Mohaupt P, Coppens S, Jaffuel A, Niehoff AC, et al. Glial fibrillary acidic protein in Alzheimer’s disease: a narrative review. Brain Communications. 2024;6(6). doi:10.1093/braincomms/fcae396

BibTeX
@article{Leipp2024,
  author = {Leipp, Florine and Vialaret, Jérôme and Mohaupt, Pablo and Coppens, Salomé and Jaffuel, Aurore and Niehoff, Ann-Christin and Lehmann, Sylvain and Hirtz, Christophe},
  title = {Glial fibrillary acidic protein in Alzheimer’s disease: a narrative review},
  journal = {Brain Communications},
  year = {2024},
  volume = {6},
  number = {6},
  doi = {10.1093/braincomms/fcae396}
}
Start for free →